Close Menu

NEW YORK – Biocept said on Tuesday that it has been awarded the CE-IVD mark for its Target Selector EGFR mutation detection assay, allowing the company to commercialize the kits throughout the European Union and other CE mark geographies.

Biocept's Target Selector technology is designed to support individual mutation assays targeting key oncogene mutations. It uses a patented "switch-blocker" method to enrich a specimen for mutations of interest, increasing sensitivity and specificity.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.